Asset profile
Goserelin
Peptide
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Goserelin: this drug | Approved | Peptide | GnRH receptor (agonist) | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | ||
| Gemcitabine | Approved | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
November 2026 (2)
2027 (13)
January 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-31 · NCT02476786 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Prostate Adenocarcinoma, Recurrent Prostate CarcinomaActive not recruiting
Est. primary completion 2027-02-01 · NCT01786265 · CT.gov ↗
What to watch
March 2027 (2)
Phase 3Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-03-15 · NCT04455750 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-30 · NCT07310420 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2/3Castration-resistant Prostate Cancer Patients with OligometastasesActive not recruiting
Est. primary completion 2027-04 · NCT02685397 · CT.gov ↗
What to watch
Phase 4Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, EndometriosisActive not recruiting
Est. primary completion 2027-04 · NCT06523530 · CT.gov ↗
What to watch
May 2027 (3)
Early phase / not applicableAllogeneic Haematopoietic Stem Cell Transplantation, Malignant Hematologic Disease, Ovarian InsufficiencyNot yet recruiting
Est. primary completion 2027-05-01 · NCT07552480 · CT.gov ↗
What to watch
Early phase / not applicableAplastic Anaemia (AA), Allogeneic Haematopoietic Stem Cell Transplantation, Ovarian InsufficiencyNot yet recruiting
Est. primary completion 2027-05-01 · NCT07552506 · CT.gov ↗
What to watch
Early phase / not applicableOvarian Insufficiency, Autologous Hematopoietic Stem Cell TransplantationNot yet recruiting
Est. primary completion 2027-05-01 · NCT07552493 · CT.gov ↗
What to watch
August 2027 (3)
Phase 4Musculoskeletal Injury, Hypogonadism, Hormonal ContraceptionRecruiting
Est. primary completion 2027-08 · NCT06455969 · CT.gov ↗
What to watch
Phase 2Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2027-08-23 · NCT04734730 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-08-31 · NCT06582446 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT07158021 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2028-04-01 · NCT03678025 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
September 2028 (2)
December 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-21 · NCT07460752 · CT.gov ↗
What to watch
2029 (2)
2030 (4)
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2/3Prostate CancerRecruiting
Est. primary completion 2030-07-31 · NCT06282588 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09 · NCT06953882 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 3Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8Recruiting
Est. primary completion 2032-12-31 · NCT04423211 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 3Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8Active not recruiting
Est. primary completion 2033-12-31 · NCT04513717 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch
2035 (1)
October 2035 (1)
Phase 3High Risk Prostate CancerNot yet recruiting
Est. primary completion 2035-10 · NCT07777263 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.